Asia Pac Allergy.  2011 Oct;1(3):123-129. 10.5415/apallergy.2011.1.3.123.

Sublingual immunotherapy in allergic rhinitis

Affiliations
  • 1Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul 110-799, Korea. csrhee@snu.ac.kr
  • 2Graduate School of Immunology, Seoul National University College of Medicine, Seoul 110-799, Korea.
  • 3Sensory Organ Research Institute, Seoul National University Medical Research Center, Seoul 110-799, Korea.
  • 4Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul 110-799, Korea.

Abstract

Current treatment options for allergic rhinitis (AR) include allergen avoidance and environmental control, pharmacotherapy, nasal surgery and immunotherapy. Among these, immunotherapy is the only therapeutic option that modifies fundamental immunologic mechanism by inducing desensitization. Specific allergen immunotherapy has been used for 1 century since 1911 and subcutaneous immunotherapy (SCIT) has been demonstrated to be effective in asthma and AR. However, SCIT has several disadvantages such as inconvenience, invasiveness and potentially severe systemic reactions. Thus, sublingual immunotherapy (SLIT) has recently received much attention around the world as a treatment for AR and is now widely used to replace the subcutaneous route. SLIT has recently been introduced in Korea and is now available for AR treatment in the Asia-Pacific region. This review offers better understanding of SLIT for AR by summarizing published articles and our previous works regarding proposed mechanisms, indication and efficacy, safety and adverse events, and compliance.

Keyword

Immunotherapy; Sublingual administration; Rhinitis
Full Text Links
  • APA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr